Stocks & Investing
Wed, August 9, 2023
[ 12:00 AM ] - WOPRAI
Fri, June 16, 2023
Tue, May 16, 2023
[ 12:00 AM ] - WOPRAI
Tue, April 4, 2023
[ 12:00 AM ] - WOPRAI
Tue, July 19, 2022
[ 12:00 AM ] - WOPRAI
Wed, May 11, 2022
[ 12:00 AM ] - WOPRAI
Mon, February 1, 2021
[ 12:00 AM ] - WOPRAI
Mon, October 19, 2020
[ 12:00 AM ] - WOPRAI
Fri, April 17, 2020
[ 12:00 AM ] - WOPRAI
Mon, March 2, 2020
[ 12:00 AM ] - WOPRAI
Fri, November 1, 2019 Ken Cacciatore Maintained (ARQT) at Buy with Decreased Target to $50 on, Aug 9th, 2023
Ken Cacciatore of TD Cowen, Maintained "Arcutis Biotherapeutics, Inc." (ARQT) at Buy with Decreased Target from $65 to $50 on, Aug 9th, 2023.
Ken has made no other calls on ARQT in the last 4 months.
There are 6 other peers that have a rating on ARQT. Out of the 6 peers that are also analyzing ARQT, 0 agree with Ken's Rating of Hold.
These are the ratings of the 6 analyists that currently disagree with Ken
- Serge Belanger of "Needham" Reiterated at Strong Buy and Held Target at $24 on, Tuesday, July 18th, 2023
- Louise Chen of "Cantor Fitzgerald" Reiterated at Buy and Held Target at $50 on, Wednesday, June 28th, 2023
- Uy Ear of "Mizuho" Reiterated at Strong Buy and Held Target at $57 on, Monday, June 12th, 2023
- Gregory Fraser of "Truist Securities" Maintained at Strong Buy with Decreased Target to $40 on, Friday, May 26th, 2023
- Jonathan Block of "Goldman Sachs" Maintained at Strong Buy with Decreased Target to $33 on, Thursday, May 11th, 2023
- Nigel Dally of "Morgan Stanley" Maintained at Buy with Decreased Target to $45 on, Wednesday, May 10th, 2023
